CSPC Pharmaceutical Group Limited (HKEX:1093) Annual Report 2021



The latest annual report of CSPC Pharmaceutical Group Limited (1093) was published on 31 Dec 2021. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.

Key Statistics - 1093 Annual Results

Amounts in CNY

Total Revenue
27.87B
Gross Profit
21.14B
EBIT
6.25B
Net Tangible Assets
25.41B
Net Income
5.61B
Capital Expenditures
-1.41B

1093 Income Statement 2021 Annual Report

As per the latest Income Statement of 1093, the Net revenue increased by ¥2.924666B (12%) compared to the previous period. The operating income in 2021 increased by ¥777.11M (14%). The net income as per the annual report was 5.61B which increased by ¥445.53M (9%) compared to previous year.

Income Statement Report (2021/2020)

20212020
Total Revenue27.87B24.94B
Gross Profit21.14B18.69B
Operating Income6.25B5.47B
Income Before Tax6.85B6.39B
Net Income5.61B5.16B

Balance Sheet - 1093 2021 Annual Report

Read further: 1093 Balance Sheet Detailed Analysis

The latest balance sheet from annual result of CSPC Pharmaceutical Group Limited showed the company increased the cash on balance sheet by ¥1.987613B (27%). The Net tangible assets of 1093 on the balance sheet were at 25.41B which is ¥3.723109B (17%) more than previous annual report. The total stockholder equity also increased by ¥3.654384B (16%) compared to previous reporting period.

Balance Sheet Statement Report (2021/2020)

20212020
Cash9.28B7.3B
Total Assets34.74B 30.07B
Long Term Debt--
Total Liabilities7.91B 6.97B
Total Shareholder Equity25.99B22.33B
Net Tangible Assets25.41B21.69B

Cash Flow Statement - 1093 2021 Annual Report

The 2021 annual cash flow statement of CSPC Pharmaceutical Group Limited showed that the net income increased by ¥445.53M (9%) compared to previous reporting period. Also the capital expenditure of 1093 decreased by ¥-53.91M (-4%).

As of 2021, the total cash from investing activities was -637.33M and total cash from financing activities was -2.2B.

Cash Flow Statement Report (2021/2020)

20212020
Net Income5.61B5.16B
Capital Expenditures-1.41B-1.36B
Dividends Paid-1.69B-1.53B
Total Cash From From Investing Activities-637.33M-2.13B
Total Cash From From Financing Activities-2.2B-1.47B

CSPC Pharmaceutical Group Limited Annual Report History

Income Statement

Income Statement history of CSPC Pharmaceutical Group Limited (HKEX:1093)

31 Dec 202131 Dec 202031 Dec 201931 Dec 2018
Total Revenue27.87B24.94B22.1B17.72B
Cost Of Revenue6.73B6.26B6.19B5.98B
Gross Profit21.14B18.69B15.91B11.74B
Research Development3.43B2.89B2B1.34B
Selling General Administrative11.45B10.32B9.46B6.84B
Non Recurring----
Other Operating Expenses----59.57M
Total Operating Expenses21.62B19.47B17.65B14.1B
Operating Income6.25B5.47B4.45B3.61B
Total Other Income Expense Net597.84M918.87M176.2M178.46M
Ebit6.25B5.47B4.45B3.61B
Interest Expense-7.66M-12.23M-32.43M-74.34M
Income Before Tax6.85B6.39B4.63B3.79B
Income Tax Expense1.16B1.16B892.81M733.76M
Minority Interest841.56M768.78M1.06B477.34M
Net Income From Continuing Ops5.69B5.23B3.73B3.06B
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Charges----
Other Items----
Net Income5.61B5.16B3.71B3.08B
Net Income Applicable To Common Shares5.61B5.16B3.71B3.08B

Balance Sheet Statement

Balance Sheet Statement history of CSPC Pharmaceutical Group Limited (HKEX:1093)

31 Dec 202131 Dec 202031 Dec 201931 Dec 2018
Cash9.28B7.3B4.12B4.34B
Short Term Investments580.42M484.29M536k443k
Net Receivables6.55B4.74B4.84B3.89B
Inventory2.48B1.86B2.54B3.19B
Total Current Assets20.34B15.92B13.7B13.8B
Long Term Investments2.92B2.71B1.49B798.54M
Property Plant Equipment9.56B8.93B9.28B6.69B
Good Will149.98M149.98M188.96M140.75M
Intangible Assets425.87M494.6M1.13B799.96M
Other Assets1.34B1.86B536.74M981.87M
Deferred Long Term Asset Charges43M117.47M34.84M18.95M
Total Assets34.74B30.07B26.32B23.22B
Accounts Payable1.77B1.36B1.53B3.27B
Other Current Liab2.25B2.38B2.7B2.48B
Other Liab631.68M574.41M473.08M440.22M
Deferred Long Term Liab41.98M14.15M8.08M7.02M
Minority Interest841.56M768.78M1.06B477.34M
Total Current Liabilities7.23B6.3B6.24B7.25B
Total Liab7.91B6.97B6.8B7.69B
Common Stock10.9B10.9B10.9B10.9B
Retained Earnings19.19B15.2B11.49B8.74B
Treasury Stock-4.15B-3.81B-3.98B-4.64B
Capital Surplus46.79M46.79M46.79M46.79M
Other Stockholder Equity-4.06B-3.71B-3.88B-4.64B
Total Stockholder Equity25.99B22.33B18.46B15.05B
Net Tangible Assets25.41B21.69B17.15B14.11B
Long Term Debt----

Cash Flow Statement

Cash Flow Statement history of CSPC Pharmaceutical Group Limited (HKEX:1093)

31 Dec 202131 Dec 202031 Dec 201931 Dec 2018
Net Income5.61B5.16B3.71B3.08B
Depreciation862.38M804.45M686.67M607.41M
Change To Netincome-446.11M-909.03M-136.99M-145.9M
Change To Account Receivables-943.55M-445.45M-196.74M-519.66M
Change To Liabilities232.57M629.28M-572.97M593.83M
Change To Inventory-617.07M601.44M509.31M-614.03M
Change To Operating Activities-59.87M894.92M-224.41M770.4M
Total Cash From Operating Activities4.64B6.74B3.78B3.8B
Capital Expenditures-1.41B-1.36B-1.88B-1.67B
Investments630.71M-450.06M261.06M-1.44B
Other Cashflows From Investing Activities269M-10.01M-267.2M-190.05M
Total Cashflows From Investing Activities-637.33M-2.13B-2.46B-3.63B
Dividends Paid-1.69B-1.53B-965.38M-782.88M
Net Borrowings-222.17M76.68M-1.63B714.11M
Other Cashflows From Financing Activities-20.16M-19.96M1.15B809k
Total Cash From Financing Activities-2.2B-1.47B-1.55B-151.39M
Effect Of Exchange Rate-2.44M2.1M1.46M3.01M
Change In Cash1.8B3.14B-217.38M19.05M
Repurchase Of Stock-263.51M-263.51M-100.71M-83.43M